With a "terrible" job market, empty labs, and mounting competition from China, the lifeblood of Kendall Square is under ...

Back in 2022, as the biotech industry’s boom was plateauing, the brash venture capitalist told executives at the biotechs he had invested in that they would be “insane” to pursue an initial ...